Pharmanutra (761) Stock Overview
A pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
761 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Pharmanutra S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €53.40 |
| 52 Week High | €57.90 |
| 52 Week Low | €38.55 |
| Beta | 0.35 |
| 1 Month Change | -5.65% |
| 3 Month Change | 37.28% |
| 1 Year Change | -0.93% |
| 3 Year Change | -14.97% |
| 5 Year Change | n/a |
| Change since IPO | 44.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 761 | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | 0.6% | -1.5% | 0.1% |
| 1Y | -0.9% | -2.1% | 13.5% |
Return vs Industry: 761 exceeded the German Personal Products industry which returned -2.1% over the past year.
Return vs Market: 761 underperformed the German Market which returned 13.5% over the past year.
Price Volatility
| 761 volatility | |
|---|---|
| 761 Average Weekly Movement | 8.8% |
| Personal Products Industry Average Movement | 5.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 761's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 761's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 136 | n/a | www.pharmanutra.it |
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It also offers iron deficiency, inflammation, mineral and vitamin, muscle and joint, sports nutrition, ophthalmic, and night rest products; and medical instrumentation and software for body bioimpedance analysis.
Pharmanutra S.p.A. Fundamentals Summary
| 761 fundamental statistics | |
|---|---|
| Market cap | €515.69m |
| Earnings (TTM) | €17.45m |
| Revenue (TTM) | €127.15m |
Is 761 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 761 income statement (TTM) | |
|---|---|
| Revenue | €127.15m |
| Cost of Revenue | €61.95m |
| Gross Profit | €65.20m |
| Other Expenses | €47.75m |
| Earnings | €17.45m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.82 |
| Gross Margin | 51.28% |
| Net Profit Margin | 13.72% |
| Debt/Equity Ratio | 29.5% |
How did 761 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 00:09 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharmanutra S.p.A. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anna Frontani | Berenberg |
| Andrea Randone | Intermonte SIM S.p.A. |
| Giorgio Tavolini | Intermonte SIM S.p.A. |